镰状细胞病：当前认识与未来选择
Sickle Cell Disease: Current Understanding and Future Options.
作者信息
Varelas Christos, Gavriilaki Eleni
机构信息
Hematology Department-BMT Unit, G .Papanicolaou Hospital, 57010 Thessaloniki, Greece.
2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54644 Thessaloniki, Greece.
出版信息
J Clin Med. 2023 Sep 13;12(18):5943. doi: 10.3390/jcm12185943.
Abstract
Sickle cell disease (SCD) is a prevalent inherited hemoglobin disorder encompassing a cluster of congenital hemolytic anemias, each distinguished by the prevalence of sickle hemoglobin (HbS) [...].
摘要
镰状细胞病（SCD）是一种常见的遗传性血红蛋白疾病，包括一系列先天性溶血性贫血，每种贫血都以镰状血红蛋白（HbS）的 prevalence[... ]为特征。 （注：原文中“prevalence”此处表述似乎有误，可能影响对整句准确理解，正常可能是“presence”之类的词，可根据实际情况调整）
相似文献
1
Sickle Cell Disease: Current Understanding and Future Options.镰状细胞病：当前认识与未来选择
J Clin Med. 2023 Sep 13;12(18):5943. doi: 10.3390/jcm12185943.
2
Current modalities of sickle cell disease management.镰状细胞病的当前管理模式。
Blood Sci. 2020 Aug 27;2(4):109-116. doi: 10.1097/BS9.0000000000000056. eCollection 2020 Oct.
3
Complement in Sickle Cell Disease: Are We Ready for Prime Time?镰状细胞病中的补体：我们准备好进入黄金时代了吗？
J Blood Med. 2021 Mar 23;12:177-187. doi: 10.2147/JBM.S287301. eCollection 2021.
4
Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.当前镰状细胞病患者管理面临的挑战——意大利经验报告。
Orphanet J Rare Dis. 2019 May 30;14(1):120. doi: 10.1186/s13023-019-1099-0.
5
The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.口服铁蛋白抑制剂 vamifeport 可改善镰状细胞病小鼠模型的血液动力学。
Blood. 2022 Aug 18;140(7):769-781. doi: 10.1182/blood.2021014716.
6
Modeling the public health impact of voxelotor in the management of sickle cell disease in France.建立数学模型评估法国用 voxolotor 治疗镰状细胞病的公共卫生影响
PLoS One. 2023 Sep 13;18(9):e0291211. doi: 10.1371/journal.pone.0291211. eCollection 2023.
7
Chronic Pulmonary Complications of Sickle Cell Disease.镰状细胞病的慢性肺部并发症
Chest. 2016 May;149(5):1313-24. doi: 10.1016/j.chest.2015.11.016. Epub 2016 Jan 13.
8
Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.镰状细胞病、血红蛋白SS型和SC型患者中的肾脏疾病
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):207-15. doi: 10.2215/CJN.03940415. Epub 2015 Dec 15.
9
Sickle cell diseases: What can nuclear medicine offer?镰状细胞病：核医学能提供什么？
Hell J Nucl Med. 2019 Jan-Apr;22(1):2-3. doi: 10.1967/s002449910950. Epub 2019 Mar 7.
10
Established and experimental treatments for sickle cell disease.镰状细胞病的既定治疗方法和实验性治疗方法。
Haematologica. 2004 Mar;89(3):348-56.
引用本文的文献
1
Cardiovascular Anesthesia and Critical Care in the French West Indies: Historical Evolution and Current Prospects.法属西印度群岛的心血管麻醉与重症监护：历史沿革与当前展望
J Clin Med. 2025 Jan 13;14(2):459. doi: 10.3390/jcm14020459.
2
The Management of Postpartum Cardiorespiratory Failure in a Patient with COVID-19 and Sickle Cell Trait Requiring Extraorporeal Membrane Oxygenation Support and Airflight Transportation.1例新冠病毒病合并镰状细胞性状患者产后心肺衰竭的管理，该患者需要体外膜肺氧合支持及航空转运
J Clin Med. 2025 Jan 2;14(1):213. doi: 10.3390/jcm14010213.
本文引用的文献
1
Mitochondria: Emerging Consequential in Sickle Cell Disease.线粒体：在镰状细胞病中崭露头角的重要因素
J Clin Med. 2023 Jan 18;12(3):765. doi: 10.3390/jcm12030765.
2
COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic.加拿大魁北克省的新冠病毒病与镰状细胞病：大流行两年后的结果
J Clin Med. 2022 Dec 12;11(24):7361. doi: 10.3390/jcm11247361.
3
Rate of Dental Extractions in Patients with Sickle Cell Disease.镰状细胞病患者的拔牙率
J Clin Med. 2022 Oct 19;11(20):6174. doi: 10.3390/jcm11206174.
4
Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study.血栓预防可降低患有中心静脉通路装置的镰状细胞病患者的静脉血栓栓塞：一项回顾性队列研究。
J Clin Med. 2022 Feb 23;11(5):1193. doi: 10.3390/jcm11051193.
5
Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center.成人镰状细胞病患者接种新冠疫苗后的免疫反应：希腊一家中心的经验
J Clin Med. 2022 Feb 11;11(4):937. doi: 10.3390/jcm11040937.
6
Complement in Sickle Cell Disease: Are We Ready for Prime Time?镰状细胞病中的补体：我们准备好进入黄金时代了吗？
J Blood Med. 2021 Mar 23;12:177-187. doi: 10.2147/JBM.S287301. eCollection 2021.
7
Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing.镰状细胞病与靶向治疗中的补体：我只知道一件事，那就是我一无所知。
Blood Rev. 2021 Jul;48:100805. doi: 10.1016/j.blre.2021.100805. Epub 2021 Jan 21.
8
Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.镰状细胞病经多线治疗后高溶血的成功转归：补体抑制的作用
Hemoglobin. 2018 Sep-Nov;42(5-6):339-341. doi: 10.1080/03630269.2018.1540353. Epub 2019 Jan 9.
9
Successful Outcome of Chronic Intrahepatic Cholestasis in an Adult Patient with Sickle Cell/ β (+) Thalassemia.镰状细胞/β（+）地中海贫血成年患者慢性肝内胆汁淤积症的成功治疗结果
Case Rep Hematol. 2014;2014:213631. doi: 10.1155/2014/213631. Epub 2014 Feb 9.
Zotero 插件